India Earnings Season: IDFC, Pharma, moody's rating
Tuesday, November 8, 2011
The ratings downgrade by moody's seems to be a political ploy addressing their own desk inadequacies as the creep on Non performing loans is unlikely to affect the private sector players and a sectoral downgrade makes no sense. Even some of the PSU banks barring UBI or Bank of India are fairly healthy producing an uptick in results without loss of discipline and despite new reform creep
The NHB announcement allowing HFCs to mark only 04% on Fixed 2 year variants of home loans will come in good for majors HDFC and others like LICHSG who could not keep up with HDFC in results
Glenmark pharma seems poised for a great jump with arnd 40% growth in sales to a $500 mln run rate for the year even at th e new Rupeee Dollar benchmarks. Opto Circuit already shows a grand 50% revenue jump to a $500mln run rate with the device orders from Japan
IDFC continues to surprise , money market eficiencies boosting its Net Interest Margins as its frevenues rose 55% mostly in the loan book and many entering a paying interst period on their loan helped NIMs too,. IDFC maintains the lowest NPAs in the business and a revenue of $2 bln annual run rate gives me confidence to carry it my portfolio always
Labels:


0 comments:
Post a Comment